anti-HER2 antibody-drug conjugate IBI354

{
  "id": "MLC-T-ONC-010741",
  "term": "anti-HER2 antibody-drug conjugate IBI354",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a camptothecin derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC IBI354, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the camptothecin derivative inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.",
  "synonyms": [
    "anti-HER2 ADC IBI354"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-her2-antibody-drug-conjugate-ibi354/"
}